Vanguard Group Inc. increased its position in DexCom Inc. (NASDAQ:DXCM) by 4.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 5,668,065 shares of the medical device company’s stock after buying an additional 238,974 shares during the period. Vanguard Group Inc. owned 6.76% of DexCom worth $449,648,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of DXCM. Wellington Management Group LLP raised its stake in DexCom by 227.1% in the first quarter. Wellington Management Group LLP now owns 5,747,553 shares of the medical device company’s stock worth $390,316,000 after buying an additional 3,990,578 shares in the last quarter. Bridger Management LLC purchased a new stake in shares of DexCom during the first quarter worth about $56,651,000. Emerald Acquisition Ltd. purchased a new stake in shares of DexCom during the second quarter worth about $47,346,000. Calamos Advisors LLC purchased a new stake in shares of DexCom during the second quarter worth about $22,764,000. Finally, Baillie Gifford & Co. raised its stake in shares of DexCom by 134.2% in the second quarter. Baillie Gifford & Co. now owns 480,978 shares of the medical device company’s stock worth $38,157,000 after buying an additional 275,568 shares in the last quarter. Hedge funds and other institutional investors own 99.37% of the company’s stock.
Shares of DexCom Inc. (NASDAQ:DXCM) opened at 85.425 on Tuesday. The company’s market capitalization is $7.17 billion. The company has a 50-day moving average price of $91.77 and a 200 day moving average price of $77.51. DexCom Inc. has a 1-year low of $47.92 and a 1-year high of $96.38.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.12. The company earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The business’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same period last year, the company earned ($0.05) earnings per share. Equities research analysts anticipate that DexCom Inc. will post ($0.57) EPS for the current year.
A number of brokerages recently issued reports on DXCM. B. Riley began coverage on DexCom in a research report on Monday, September 26th. They issued a “neutral” rating and a $97.00 target price on the stock. Zacks Investment Research lowered DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Jefferies Group reissued a “buy” rating and issued a $98.00 target price on shares of DexCom in a research report on Wednesday, August 3rd. JPMorgan Chase & Co. reissued a “buy” rating and issued a $100.00 target price on shares of DexCom in a research report on Wednesday, August 3rd. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $100.00 target price (up previously from $93.00) on shares of DexCom in a research report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $95.08.
In related news, Director Mark G. Foletta sold 1,800 shares of the stock in a transaction that occurred on Wednesday, September 7th. The stock was sold at an average price of $94.63, for a total transaction of $170,334.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jorge A. Valdes sold 32,000 shares of the stock in a transaction that occurred on Monday, July 11th. The shares were sold at an average price of $79.36, for a total value of $2,539,520.00. Following the sale, the insider now directly owns 123,667 shares of the company’s stock, valued at $9,814,213.12. The disclosure for this sale can be found here. 2.80% of the stock is owned by insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.